EZH2在伴微乳头结构肺腺癌中的表达及预后意义
| 作者: |
1郭丹,
1王安琪,
1谢婷,
2孙健
1 中国医学科学院北京协和医院医学科学研究中心，北京 100730 2 中国医学科学院北京协和医院病理科，北京 100730 |
| 通讯: |
孙健
Email: sunjian0720@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.06.004 |
| 基金: | 中国医学科学院医学与健康科技创新工程(2017-I2M-1-001，2017-I2M-2-001)。 |
摘要
目的：通过研究EZH2在伴微乳头结构肺腺癌(pulmonary adenocarcinoma with micropapillary pattern，MPPAC)肿瘤组织中的表达，分析其与MPPAC临床病理特征的相关性，探讨EZH2在MPPAC发生发展及预后评估中的可能作用。方法：采用组织芯片技术和免疫组织化学检测84例MPPAC患者中EZH2蛋白的表达，分析其表达与各临床病理特征的相关性，并应用Kaplan-Meier法及log-rank检验分析EZH2表达与MPPAC患者生存率的关系。结果：免疫组织化学的结果显示54.8%的MPPAC患者呈现EZH2阳性表达，统计学结果表明EZH2的表达与MPPAC患者的性别、年龄、肿瘤直径、淋巴结转移、TNM分期均无明显相关性，而与吸烟密切相关，且差异有统计学意义(P<0.05)。MPPAC中EZH2阳性和阴性组的累计生存率差异不显著(P>0.05)，阳性组患者的术后无瘤生存时间明显低于阴性组，Cox回归分析显示随时间的延长，患者生存率逐渐下降，死亡风险不断增大。结论：EZH2的表达上调可能与MPPAC的发生和预后相关，为进一步探讨EZH2在MPPAC中的作用提供了理论基础。
关键词：
伴微乳头结构肺腺癌；EZH2；免疫组织化学；肿瘤发生发展；预后
Expression of EZH2 in micropapillary-predominant subtype pulmonary adenocarcinoma and its prognostic significance
CorrespondingAuthor: SUN Jian Email: sunjian0720@126.com
DOI: 10.3978/j.issn.2095-6959.2021.06.004
Foundation: This work was supported by Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine, China (2017-I2M-1-001, 2017-I2M-2-001).
Abstract
Objective: To explore the role of EZH2 in the tumorigenesis, progression, and prognosis of pulmonar y adenocarcinoma with micropapi l lar y pattern (MPPAC) by investigating the expression of EZH2 in human (MPPAC) and its correlation with the clinicopathologic characteristics. Methods: The expression of EZH2 were analyzed in 84 cases of MPPAC tissue with tissue microarray and immunohistochemistry (IHC), and the relationship of EZH2 expression and clinicopathologic characteristics, and prognosis were analyzed. The relationship between EZHZ espression and overall survival of patients was estimated by the Kaplan-Meier method and the log-rank test. Results: The immunohistochemical data showed that 54.8% of the MPPAC expressed EZH2, and its positive expression was highly correlated with smoking (P<0.05), but there was no significant correlation with gender, age, tumor diameter, lymph node metastasis, and TNM staging in MPPAC patients. There was no significant difference in the cumulative survival rate between the EZH2-positive group and the EZH2-negative group in MPPAC (P>0.05), and the postoperative tumor-free survival time of patients in the positive group was significantly lower than that in the negative group. The Cox regression analysis indicated that with the extension of time, the survival rate of patients decreased gradually and the risk of death increased continuously. Conclusion: The up-regulation expression of EZH2 may be closely related to the tumorigenesis, progression and prognosis of MPPAC, which provides a theoretical basis for further exploring the function of EZH2 in MPPAC.
Keywords：
pulmonary adenocarcinoma with micropapillary pattern; EZH2; immunohistochemistry; umorigenesis and progression; prognosis